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Abstract
Introduction: Bronchial asthma is a disease characterized by chronic inflammation of the airways. At present, about 
235-300 million people suffer from asthma, and this number continues to grow. This pathology is also common in chil-
dren. It causes significant social and economic damage worldwide. Severe forms of asthma are difficult to treat. Thus, 
a continuous improvement of doctors’ knowledge in this field is of great importance.
Methods: The analysis of an anonymous survey of physicians and senior medical students was used in the research.
Results: The study revealed both an average level of basic knowledge in asthma etiology and pathogenesis among the 
physicians and senior medical students and the significant differences in their knowledge regarding clinical picture and 
treatment of asthma. Only 49.2% of students and 56.0% of doctors were able to choose the correct definition of asthma 
from the suggested answers; 65.7% of students and 69.9% of doctors correctly indicated the main clinical and laboratory 
markers of asthma; 60.2% of students and 91.0% of doctors determined the correct combination of drugs in one delivery 
device; and 75.9% of students and 91.2% of doctors selected the correct basic asthma therapy depending on the severity.
Conclusion: Basing on the results obtained it was recommended to introduce additional educational activities on the 
diagnosis and therapy of asthma among medical majors and physicians.
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Introduction
Bronchial asthma is a challenging issue of a modern health 
care system. According to the World Health Organization 
(WHO), it is spread worldwide regardless of the develop-
ment level of countries (GINA 2014, GINA 2017).
Bronchial asthma (BA) is a heterogeneous disease, 
characterized by chronic inflammation of the airways. 
The main symptoms of asthma are wheezing, shortness 
of breath, chest tightness and cough. Symptoms vary in 
duration and intensity, depending on temporary bronchial 
obstruction (GINA 2014-2018, Namazova-Baranova et 
al. 2009, Pearce et al. 2007).
The information on asthma prevalence is different, 
which is due to the following aspects: different approa-
ches used for disease recognition, late diagnosis, differen-
ces in the degree of incidence among countries. WHO’s 
major epidemiological studies report that asthma inciden-
ce is from 1% to 18%. Such a wide range of results is 
due to the assessment of an epidemiological situation in 
countries with different levels of social and economic de-
velopment. Countries with poor social development and 
environmental pollution have both high rates of asthma 
and an increased risk of severe asthma development with 
complications and mortality. To date, it is estimated that 
235-300 million people suffer from asthma. Scientists say 
that this figure grows by 50% every 10 years (Chuchalin 
et al. 2014, GINA 2014, Partridge et al. 1998).
According to the statistics, there were 383.000 deaths 
due to asthma in 2015. On average, about 250.000 people 
die from asthma every year. Fifteen million DALYs are 
detected yearly due to this pathology (DALY is Disabili-
ty Adjusted Life Year) (Federal clinical guidelines 2018, 
GINA 2017, Stewart et al. 2001).
It is important to note that asthma causes significant 
social and economic damage. There was a study to as-
sess the impact of asthma in many countries of Asia, Latin 
America, Europe, as well as in the USA. Asthma causes 
direct and indirect costs such as: cost of drugs, cost of 
hospitalization, days of disability, and premature deaths. 
Costs depend on the level of control over the disease, 
prophylaxis and how efficient is prevention of exacerba-
tions (GINA 2014, GINA 2017, Pertseva and Gashinova 
2007, Sergeeva et al. 2015).
Asthma is one of the common pathologies in children, 
with presumably 5% to 10% of world’s children suffe-
ring from it. Diagnosing asthma in children is challenging 
since it often cannot be recognized either because of an 
unclear etiology or because children are diagnosed with 
asthmatic bronchitis. Due to the late diagnosis, disease 
progresses, and the therapy starts with administering 
higher initial doses of drugs (Avdeev et al. 2018, Federal 
clinical guidelines 2018, Namazova-Baranova et al. 2007, 
Papadopoulos et al. 2012, Partridge et al. 1998).
Of special consideration is so-called severe asthma. 
According to statistics, about 5-20% of patients suffer 
from severe BA. This form is characterized by a more se-
vere course compared to its “ordinary” forms, when the 
traditional approach to its therapy is of little assistance. 
Individual disease phenotypes should be singled out in 
order to develop a personalized approach to treatment of 
such patients (Avdeev et al. 2018, Nenasheva 2012, Ser-
geeva et al. 2015).
Considering the above-mentioned, it is recommended 
to assess physicians’ and medical majors’ knowledge in 
asthma therapy, to find gaps in their knowledge and to 
bridge them.
Aim: to determine the level of basic knowledge of the 
treatment of bronchial asthma among physicians and me-
dical majors in their fifth-sixth years of studies.
Materials and methods
The survey was conducted within the first phase of the 
“ASSA-II” project started in 2017 – a study aimed to as-
sess the knowledge of specialists in the field of bronchial 
asthma (the full name of the project is “Assessment of 
Senior Medical Students in the Field of Bronchial Asth-
ma”). So far, the results of the survey conducted in eight 
centers of Russia and the Ukraine have been obtained and 
analyzed. The survey was conducted among both Medical 
Care majors in their fifth-sixth years from four cities (Bel-
gorod, Voronezh, Dnipro and Chelyabinsk) and physici-
ans from eight cities (Belgorod, Voronezh, Krasnodar, 
Chelyabinsk, Smolensk, Saratov, Lipetsk and Dnipro). 
The study has been also started in Moscow, Ufa, Ka-
zan, Krasnoyarsk and Bishkek, and currently the data for 
the further analysis is being accumulated.
The study was conducted in compliance with the prin-
ciples of the Helsinki Declaration.
All the students were enrolled in standard educational 
programs. It is necessary to emphasize that this method of 
knowledge assessment is relative, and was specially deve-
loped for this study, thus, cannot fully reflect the general 
level of education quality at university.
The students were questioned with a help of an ori-
ginal questionnaire, which had been developed in accor-
dance with the GINA-2014-2017 provisions (GINA 2014, 
GINA 2017), and consisted of 12 questions. The respon-
dents could give only one correct answer, the option “not 
sure” was also available. Approbation (validation) of the 
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preliminary and final versions of the questionnaire was 
completed with a help of cross-testing within the group 
of co-authors and on pilot groups of doctors and students 
in the regions under study. During this period, the options 
for one question of the questionnaire were adjusted.
The respondents were asked to specify their year of 
studies and/or major, indicating whether it was the first 
or second time when s/he had taken the questionnaire, 
after which, s/he was supposed to proceed with the ques-
tionnaire. The respondents did not indicate their names, 
which helped to obtain more independent results without 
the factor of possible evaluation influencing the respon-
dents.
The respondent was awarded 1 point for each cor-
rect answer, 0.5 point – for an incomplete answer (when 
choosing both correct and incorrect answers) and 0 point 
for the incorrect answer. Thus, with all the correct ans-
wers, the maximum average score was 1.0.
For each respondent, the average score was calculated, 
the average score for individual questions, the average 
score for the centers (cities) and the average score for the 
entire questionnaire. The average level of response com-
pleteness (ARC) was calculated as the average of all the 
correct, partially correct and incorrect answers, an equi-
valent being the average level of correct answers. Also, 
separately were analyzed the patterns of answers to in-
dividual questions. All the information entered into the 
questionnaires was then entered to an electronic database 
and processed using MICROSOFT EXCEL applications. 
Statistical data were processed through the analysis of 
fourfold and arbitrary contingency tables using the Pears-
on’s chi-square (x2) test and, if necessary, with the Yates’ 
correction or the calculation of Fisher’s exact test.
The overall results of the first part of the project (AS-
SA-I, 2014-2016) were published in Farmateka, Journal 
No.5, 2019 (Bontsevich et al. 2019), and the partial re-
sults for 2014-2015 were published in the European Re-
spiratory Journal (Bontsevich et al. 2014, Bontsevich et 
al. 2015). The brief results of the project ASSA-II were 
also submitted and accepted as abstracts for the European 
Respiratory Congress 2019.
Results 
The survey involved 249 students (45.0% – from Bel-
gorod, 31.7% – from Voronezh, 16.9% – from Chelya-
binsk, and 6.4% – from Dnepr) and 219 doctors (34.2% 
– from Belgorod, 18.7% – from Voronezh, 4.6% – from 
Krasnodar, 9.6% – from Chelyabinsk, 7.3% – from Smo-
lensk, 8.2% – from Saratov, 7.3% – from Lipetsk and 
10% – from Dnepr).
The average level of correct answers to all questions 
was 72.6% among students and 83.8% among doctors. 
Differences between the centers ranged from 49.2% to 
90.0% for students and from 56.0% to 95.6% for doctors.
The lowest level of correct answers – only 49.2% of 
students and 56.0% of doctors – was obtained to the ques-
tion concerning choosing the correct definition of asthma 
from the suggested answers, pdoct-stud>0.05; 65.7% of stu-
dents and 69.9% of doctors correctly indicated the main 
clinical and laboratory markers of asthma, pdoct-stud>0.05. 
The maximum average level of correct answers was regis-
tered for the following questions: the correct combination 
of drugs in one delivery device (60.2% of students and 
91.0% of doctors, pdoct-stud<0.001) and the correct basic 
asthma therapy depending on the severity (75.9% of stu-
dents and 91.2% of doctors, pdoct-stud<0.001).
Discussion
The first question required the respondents to choose 
the best definition of asthma from five possible options. 
Half of students (49.2%, varying from 43.8% to 56.0% 
in different centers) and 56.0% of doctors (from 24.7% 
to 80.5% in different centers) answered correctly, pdoct-
stud>0.05 (Fig. 1).
In the next question of the questionnaire, it was neces-
sary to select a possible trigger of an asthma attack from 
the following list of options: indoor allergens, physical 
stress, cold, administration of non-steroidal anti-inflam-
matory drugs, or “all the above” (the correct answer) 
(Avdeev 2005, Chuchalin 2017, GINA 2014). The correct 
answers were given by 92.4% of doctors (varying from 
86.4% to 100% in different cities) and 78.1% of students 
(from 73.2% to 100%), pdoct-stud<0.001 (Fig. 2).
According to statistical data, bronchial hyperreacti-
vity triggered by irritants ranks first in asthma patho-
genesis. It is accompanied by stimulation of membra-
Figure 1. Responses to the question about BA definition
Figure 2. Responses to the question about asthma triggers
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ne phospholipids metabolism and by the release of the 
following inflammatory mediators from mast cells: his-
tamine, acetylcholine, serotonin, proteases, eosinophil 
chemotaxis factor and neutrophils. Primary inflamma-
tory mediators and metabolic products of arachidonic 
acid –prostaglandins (GD2) and leukotrienes (LTC4) 
– cause an increase in vascular permeability, an ede-
ma of the respiratory tract mucosa, a bronchial smooth 
muscle spasm, infiltration of tissue with eosinophils and 
neutrophils and strengthen bronchial secretions (British 
Guideline 2008, Chuchalin et al. 2014, GINA 2014, Zu-
reik et al. 2002).
The third question of the questionnaire was about ast-
hma pathogenesis. The respondents were to choose a key 
factor of asthma pathogenesis from the following options:
1. Bronchial hyperreactivity (correct option)
2. Body allergization
3. Hypersensitivity of respiratory tract mucosa
4. Defective bronchial muscles tone 
5. Not sure
Two thirds – 66.3% (from 53.6% to 88.1% in different 
centers) of students and 82.1% of doctors (from 66.9% to 
93.8% in different centers) gave the correct answer, pdoct-
stud<0.001 (Fig. 3).
The main laboratory and instrumental markers to di-
agnose asthma are a decreased forced expiratory volume 
within the 1st second (FEV1), increased IgE and eosinop-
hilia (Avdeev 2005, Chuchalin et al. 2014, GINA 2014, 
Nenasheva 2012). In the next question, the respondents 
were required to specify the most appropriate instrumental 
and laboratory asthma marker out of the proposed options:
1. decreased lung capacity, normal FEV1, increased 
IgE, eosinophilia
2. increased FEV1, decreased IgE, specific changes on 
chest radiographs 
3. decreased FEV1 and lung capacity, increased IgM, 
lymphocytosis
4. increased FEV1, normal lung capacity, decreased IgE, 
neutrophilia, specific changes on chest radiographs
5. decreased FEV1, increased IgE, eosinophilia (cor-
rect answer)
6. Not sure
Almost the same number of respondents – 65.7% (from 
60.8% to 77.4% in different cities) of students and 69.9% 
of doctors (from 50.0% to 95.2%) – gave the correct ans-
wer, pdoct-stud>0.05 (Fig. 4).
The next question was about the asthma diagnostic 
methods. The respondents had to indicate an appropriate 
method of examination from the following options: ra-
diography, bronchography, bronchoscopy, and pulmonary 
function test (correct answer). The majority of the sur-
veyed answered correctly (87.6% of students and 92.0% 
of doctors, varying from 85.7% to 93.8% in different cen-
ters and from 80.6% to 100% in different centers, pdoct-
stud>0.05) (Fig. 5).
The sixth question required the respondents to specify 
the severity of asthma according to GINA classification 
(Table 1). 
The majority of the respondents gave the correct ans-
wer: 77.1% of students and 78.8% of doctors (from 64.3% 
to 93.8% and from 61.1% to 100% in different students’ 
and doctors’ centers, respectively, pdoct-stud>0.05) (Fig. 6).
According to modern clinical guidelines, asthma treat-
ment has to be carried out under continuous monitoring 
(British Guideline 2008, Federal clinical guidelines 2018, 
Agarwal et al. 2015, Sears et al. 2003). Asthma monito-
ring is an assessment of symptoms severity, or to what 
extent they have been reduced or eliminated by the con-
ducted therapy. It consists of symptoms control and risk 
factors for the future negative outcomes. Poor symptoms 
control complicates the patient’s life and is a risk factor 
for exacerbations.
Control is determined by using an asthma control 
test™ (ACT™). This is a questionnaire (Table 2) consis-
ting of five questions, with the help of which control over 
Figure 3. Responses to the question about bronchial asthma 
pathogenesis
Figure 4. Responses to the question about the main laboratory 
and instrumental markers of bronchial asthma
Figure 5. Responses to the question about the main methods of 
bronchial asthma diagnostics
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Table 1. Classification of asthma severity by clinical features before treatment according to GINA  (British Guideline 2008, GINA 
2014, Chuchalin  et al. 2014)
Level 1: Intermittent Level 2: Mild persistent Level 3: Moderate persistent Level 4: Severe persistent
◦ Symptoms less than once a week ◦ Symptoms more than once a 
week but less than once a day
◦ Symptoms daily ◦ Symptoms daily
◦ Brief exacerbations ◦ Exacerbations may affect activity 
and sleep
◦ Exacerbations may affect activity 
and sleep
◦ Frequent exacerbations
◦ Nocturnal symptoms not more 
than twice a month
◦ Nocturnal symptoms more than 
twice a month
◦ Nocturnal symptoms more than 
once a week
◦ Frequent nocturnal asthma 
symptoms
◦ Daily use of inhaled short-acting 
β2-agonist
◦ Limitation of physical activities
◦ FEV1 or PEF>80% pred ◦ FEV1 or PEF>80% pred ◦ FEV1 or PEF 60–80% pred ◦ FEV1 or PEF<60% pred
◦ PEF or FEV1 variability<20% ◦ PEF or FEV1 variability 20–30% ◦ PEF or FEV1 variability>30% ◦ PEF or FEV1 variability>30%
Note: FEV1: forced expiratory volume in one second; PEF: peak expiratory flow; % pred: % predicted.
Table 2. Asthma control according to GINA for adults and children (Federal clinical guidelines 2018).
Symptoms in the past 4 weeks Asthma symptom control
Well-controlled Partly controlled Uncontrolled
Daytime symptoms more than twice/week (or once/week*)
No criterion applies 1–2 criteria apply 3–4 criteria apply Any night waking due to asthmaReliever needed more than twice/week
Any limitation of daily activity due to asthma
Note: * – In children ≤5 years
bronchial asthma is measured in patients over 12 years 
old (Chuchalin 2017, Federal clinical guidelines 2018, 
Horak et al. 2016, King and Hanania 2010).
In the next question, it was necessary to indicate the 
existing levels of disease control. The following options 
were proposed:
1. Level 1, level 2А, level 2B, level 3 
2. Satisfactory, unsatisfactory
3. Controlled, partly controlled, uncontrolled (correct 
answer)
4. Inhalation, tableted, intravenous
5. Not sure
The correct answer was given by 71.5% of students 
(from 61.6% to 87.5% in different cities) and 85.8% of 
doctors (from 61.1% to 100%), pdoct-stud<0.001) (Fig. 7).
The best way of monitoring asthma at home is peak 
expiratory flow rate (PEF) measurements made by using 
a peak flow meter. PEF is the maximum speed at which 
air can pass through the airways during maximum rapid 
expiration after the deepest possible breath. It allows to 
evaluate the response to the therapy and to analyze the in-
citing agents (Brodskaya and Belevsky 2016, Chuchalin 
2017, Federal clinical guidelines 2018). Peak flow meters 
are relatively inexpensive, portable and easy to operate.
In the next question of the questionnaire, it was requi-
red to indicate the correct option of asthma self-control 
at home:
1. Breathing test
2. Peakflowmetry (correct answer)
3. Pneumometry
4. Spirography
5. Not sure
The correct answer was given by 71.9% of students 
(from 64.3% to 81.0% in different cities) and 86.5% of 
doctors (from 75.3% to 100%), pdoct-stud<0.001) (Fig. 8).
Asthma exacerbations (synonyms: BA attacks, or acu-
te BA) are episodes of increasing shortness of breath, 
cough, wheezing, or chest congestion, requiring changes 
in the usual regimen of therapy. An exacerbation of BA 
is characterized by a decreased PEF and FEV1. They can 
develop in patients with an already established diagnosis 
of asthma or can be observed for the first time. The deve-
Figure 6. Responses to the question about classification of asth-
ma severity
Figure 7. Responses to the question about asthma control
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lopment rate of asthma exacerbations may vary signifi-
cantly in different patients — from a few minutes or hours 
to 10–14 days. Exacerbations relief time also varies from 
5 to 14 days (Belevsky 2013, Chuchalin 2017, GINA 
2017). With an adverse course of asthma exacerbation, 
the status asthmaticus – an episode of an acute respiratory 
failure (life-threatening asthma; nearly fatal asthma) – is 
highly likely to develop (Table 3).
In the ninth question, the respondents were required to 
select the correct option for a severe asthma attack:
1. Silent chest
2. Status asthmaticus (correct version)
3. Angina pectoris
4. Paroxysm
5. Not sure
Almost all the students and doctors chose the correct 
answer – 90.0% of students and 95.6% of doctors (from 
87.5% to 95.2% and from 92.7% to 100% in different ci-
ties, respectively, pdoct-stud<0.05) (Fig. 9).
The last questions were aimed at determining the level 
of knowledge in the following aspects: basic therapy pre-
scription, drugs of choice in the treatment of asphyxiation, 
combination drugs in management of patients with asthma.
The modern view on the treatment of asthma is aimed 
at achieving control over the symptoms of the disease 
and the prevention of complications and adverse out-
comes. To date, a stepwise therapy of asthma is pre-
scribed, depending on the symptoms and condition of 
the patient. For mild to moderate exacerbations, the best 
way to quickly eliminate bronchial obstruction is to re-
peatedly use fast-acting inhaled β2-agonists (2 to 4 in-
halations every 20 minutes for the first hour). After the 
first hour, the required dose of β2-agonists will depend 
on the severity of the exacerbation (Avdeev et al. 2016, 
Aysanov and Kalmanova 2009, Belevsky 2013, Ichinose 
et al. 2017).
The tenth question was about choosing a drug to use 
first of all in asthma attack treatment:
1. Mechanical lung ventilation
Table 3. Classification of BA exacerbations (Chuchalin A.G.2017)
Moderate asthma exacerbation One of the following criteria:
◦ Strengthening the symptoms
◦ PEF 50-75% of the best or calculated result
◦ Increased frequency of using ambulance drugs ≥50% or their additional use through a nebulizer
◦ Night awakenings due to the onset of symptoms of asthma and requiring the use of first-aid drugs
Severe exacerbation of asthma One of the following criteria:
◦ PEF 30-50% of the best values
◦ Respiratory rate ≥25/ min
◦ Pulse ≥110/min
◦ Inability to pronounce a phrase on one breath
Life threatening asthma One of the following criteria:
◦ PEF<33% of the best values
◦ SpO2<92%
◦ PaO2<60mm Hg
◦ Normocapnia (PaCO2 – 35-45mmHg) 
◦ "Silent Chest"
◦ Cyanosis
◦ Weak breathing effort
◦ Bradycardia
◦ Hypotension
◦ Fatigue
◦ Stupor
◦ Coma
Nearly fatal asthma ◦ Hypercapnia (PaCO2>45 mm Hg) 
and/or
◦ Need for mechanical lung ventilation
Figure 8. Responses to the question about the methods of asth-
ma self-control
Figure 9. Responses to the question about definition of a severe 
asthma attack
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2. β2 short-acting agonists (correct version)
3. Inhaled glucocorticoids
4. Systemic hormones
5. Aminophylline
6. Not sure
The correct answer was chosen by 77.7% of students 
(from 70.2% to 93.8% in different cities) and 84.6% of 
doctors (from 77.0 % to 100%), pdoct-stud>0.05).
In the next question, the respondents were asked to 
choose a drug therapy for asthma depending on the symp-
toms and the risk of exacerbations (GINA 2017). It was 
necessary to specify the right option for the basic treat-
ment of moderate asthma (Avdeev et al. 2016, Chuchalin 
2017, Federal clinical guidelines 2018, Fitzpatrick and 
Moore 2017, Ichinose et al. 2017):
1. Inhaled glucocorticoid + aminophylline
2. Inhaled glucocorticoid + long-acting β2-agonist 
(the correct option)
3. Aminophylline + long-acting β2-agonist
4. M-anticholinergic + long-acting β2-agonist 
5. Not sure
The correct answer was chosen by 75.9% of students 
(from 52.4% to 87.5% in different cities) and 91.2% of 
doctors (from 77.8% to 100%), pdoct-stud<0.001).
An efficient asthma treatment achieved by adminis-
tering the combination of inhaled glucocorticoids and a 
long-acting β2-agonist led to an introduction into clini-
cal practice of medications which combine fixed doses 
of inhaled corticoids and a long-acting β2-agonist in one 
inhaler (Avdeev et al. 2016, Belevsky 2013, Fitzpatrick 
and Moore 2017, GINA 2014, GINA 2017, Ichinose et al. 
2017). In the twelfth question, it was required to choose 
the correct combination of drugs in one delivery device 
from the following options:
1. Inhaled glucocorticoid + aminophylline
2. Inhaled glucocorticoid + long-acting β2-agonist of 
(the correct option)
3. Aminophylline + long-acting β2-agonist
4. M-anticholinergic + β-blocker
5. Not sure
Only 60.2% of the surveyed students and 91.0% of the 
doctors (from 33.3% to 75.0% and from 70.0% to 100% 
in different cities, respectively) were able to give the cor-
rect answer, pdoct-stud<0.001.
Conclusion
The survey among the senior students of medical uni-
versities and physicians within the multicenter study 
(ASSA-II project) revealed an average level of medi-
cal majors’ and physicians’ knowledge in asthma ba-
sics (definition, etiology, pathogenesis, clinical picture, 
treatment and prevention). The most difficult questions 
for both groups of the respondents were the following 
questions: asthma recognition, instrumental and labora-
tory markers of asthma and asthma control levels. The 
students also struggled with the questions about asthma 
pathogenesis, the choice of drugs for exacerbation re-
lief, the main drugs for basic therapy and combinati-
on of drugs for asthma treatment. In general, it should 
be emphasized that doctors did better with most of the 
questions (Fig. 10), which can indicate lack of practical 
experience among students.
Thus, both students and doctors would make quite a 
big number of mistakes in diagnostics and decision-ma-
king about treatment of asthma, which leads to late diag-
nosis and late therapy administration, poor asthma con-
trol, exacerbations and adverse outcomes, reducing the 
quality of patients’ life and, consequently, decreasing the 
compliance.
In the authors’ view, the number of academic hours and 
practical lessons at universities is still insufficient for ta-
king a closer look at the topics related to respiratory sys-
tem, in particular, obstructive diseases, which is needed 
for an adequate preparation of a future practitioner. The 
obtained results prove the need to conduct additional edu-
cational activities on diagnostics and therapy of asthma 
and, hence, the delivery of timely and effective care.
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